Sempuku T, Ohgushi H, Okumura M, Tamai S
Department of Orthopaedic Surgery, Saiseikai Chuwa Hospital, Sakurai, Japan.
J Orthop Res. 1996 Nov;14(6):907-13. doi: 10.1002/jor.1100140610.
Hydroxyapatite ceramics facilitate osteogenesis but cannot induce bone formation by themselves. We studied the feasibility of bone formation supported by allogeneic bone marrow cells in porous hydroxyapatite ceramics. Coralline hydroxyapatite discs were soaked in a marrow cell suspension harvested from either ACI (RT1a), Lewis (RT1(1)), or Fischer 344 (RT1(1v)) male rats, and these discs were implanted subcutaneously into 56 male Fischer 344 rats. FK-506 (tacrolimus hydrate), an immunosuppressant, or saline was injected intramuscularly into the recipients every day for 2 weeks after surgery, and additional injections were given to 19 of the rats every 2 days for 2 more weeks. Neither of the mismatched major (ACI rat) or minor (Lewis rat) marrow cell transplants showed any bone formation without administration of FK-506. However, in rats treated with FK-506, bone formed in the pores of all the three types of ceramics implanted, which each contained the marrow cells from one of the three kinds of rats used. There were no differences among the three groups of donors with regard to the bone formation ratio. We previously reported that subcutaneous implantation of porous hydroxyapatite combined with isogeneic marrow cells resulted in consistent bone formation, even at ectopic sites. Since it would be difficult to harvest a large number of autologous marrow cells in clinical cases, we attempted to use allogeneic marrow cells and have shown the allogeneic murine marrow cells to have osteogenic potential.
羟基磷灰石陶瓷促进骨生成，但自身不能诱导骨形成。我们研究了多孔羟基磷灰石陶瓷中同种异体骨髓细胞支持骨形成的可行性。将珊瑚羟基磷灰石圆盘浸泡在从ACI（RT1a）、Lewis（RT1(1)）或Fischer 344（RT1(1v)）雄性大鼠采集的骨髓细胞悬液中，然后将这些圆盘皮下植入56只雄性Fischer 344大鼠体内。术后2周每天给受体肌肉注射免疫抑制剂FK-506（水合他克莫司）或生理盐水，另外19只大鼠每2天额外注射一次，持续2周。在未给予FK-506的情况下，不匹配的主要（ACI大鼠）或次要（Lewis大鼠）骨髓细胞移植均未显示任何骨形成。然而，在用FK-506治疗的大鼠中，植入的所有三种类型陶瓷的孔隙中均形成了骨，每种陶瓷都含有来自所用三种大鼠之一的骨髓细胞。三组供体在骨形成率方面没有差异。我们之前报道过，皮下植入多孔羟基磷灰石与同基因骨髓细胞相结合，即使在异位部位也能持续形成骨。由于在临床病例中很难采集大量自体骨髓细胞，我们尝试使用同种异体骨髓细胞，并已证明同种异体小鼠骨髓细胞具有成骨潜力。
